Strategic Growth SEBIA’s acquisition of ZEUS Scientific expands access to autoimmune and infectious disease diagnostics with an enhanced product portfolio, presenting cross-sell opportunities for high-sensitivity serology systems and novel biomarkers like AccuCardia to broaden cardiovascular risk assessment offerings.

Expanded Test Menu Recent launches including the dIFine 30 System and the AccuCardia predictive cardiac biomarker create a pathway to upsell integrated diagnostic workflows, enabling labs to consolidate immunofluorescence, slide processing, and novel biomarker testing under one vendor.

Lyme Disease Focus ZEUS’s FDA-cleared Borrelia Modified Two-Tiered Testing algorithm positions the company as a leader in early Lyme disease detection, offering a sales angle to healthcare providers seeking improved sensitivity and faster workflow in infectious disease testing.

Public Confidence A track record of FDA clearances and rapid test development demonstrates regulatory credibility and responsiveness to market needs, which can be leveraged to win RFPs and expand footprint in hospital, reference lab, and integrated delivery networks.

Growth Momentum Ongoing expansion into predictive biomarkers and digital integration with platforms like Salesforce and Pardot suggests opportunities to offer end-to-end data management, remote monitoring, and analytics services to optimize assay performance and reporting for customers.